English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Myxobacteria are a class of prokaryotes with complex multi-cellular behavior and could produce various bioactive materials. Forty-eight strains stored in Key Lab of Microbial Diversity Research and Application of Hebei Province were screened by MTT methods with L1210, Hela and normal diploid human embryonic lung fibroblast cell lines as screening models. The results demonstrated that most of the strains could inhibit cancer cells. The inhibition rates to L1210 and Hela are about 78.5% and 59%, respectively. Strain 910018 and 920036 showed higher inhibition activity to cancer cells L1210 and Hela in compare with lower inhibition activity to normal diploid human embryonic lung fibroblast cell line. Therefore, the extracts from the two strains have the potentials as anticancer drugs and were undertaken in vivo anticancer experiments. The results showed that strain 910018 and 920036 could inhibit mice transplanted liver cancer cells H22. The inhibition rate of low doses group of strain 910018 is 69.37% and that of strain 920036 is 54.98%. Therefore, the two strains could be good candidates for producing of anticancer drugs

Screening of Anticancer Materials from Myxobacteria and Evaluation of Their Bioactivity in Vivo